Virpax Pharmaceuticals, Inc.(VRPX)Earnings, Financials & Key Ratios

VRPX•NASDAQ

$0.01

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryDrug Delivery Technology Platforms

AboutVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.Show more

Revenue$0
EBITDA-$12M+21.2%
Net Income-$12M+20.6%
EPS (Diluted)-70.91-446.7%
ROE-2364.82%-1341.2%

VRPX Price & Volume

Virpax Pharmaceuticals, Inc. (VRPX) stock price & volume — 10-year historical chart

Loading chart...

Preclinical Development Burn Threatens Operational Continuity

Investment Thesis • Updated 2024Q4

VerdictNeutral

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent liquidity exhaustion risk

Key Thesis Takeaways

Virpax Pharmaceuticals remains a high-risk, pre-revenue entity entirely dependent on external financing to sustain its proprietary drug delivery research.
The company's inability to generate commercial revenue, combined with a rapid erosion of its asset base from $23.6 million in 2022Q3 to $1.6 million in 2024Q4, creates a precarious outlook for long-term viability.
Investors should monitor the company's ability to secure additional capital, as the current liquidity profile suggests an imminent risk of operational exhaustion before reaching critical clinical milestones.

Verdict Logic

Negative: The company's cash balance of only $1.5 million against $2.5 million in total liabilities suggests a critical liquidity shortfall that necessitates immediate and potentially dilutive capital market intervention.

VRPX Growth Metrics

Virpax Pharmaceuticals, Inc. (VRPX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM19.87%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM55.44%

Return on Capital

10 Years-671.94%

5 Years-671.94%

3 Years-872.54%

Last Year-2367.31%

Peers Comparison

Key metrics vs top competitors for Virpax Pharmaceuticals, Inc. (VRPX)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
VRPXVirpax Pharmaceuticals, Inc.Current	$0.01	$47.22K	-0.00	—	—	-2364.82%	—
NKTRNektar Therapeutics	$74.90	$1.46B	-7.70	-43.89%	-284.18%	-87%	—
PCRXPacira BioSciences, Inc.	$25.82	$1.02B	161.38	3.63%	1.27%	1.31%	—
PRAXPraxis Precision Medicines, Inc.	$323.95	$9.36B	-24.03	-100%	—	-43.02%	—
ABBVAbbVie Inc.	$254.65	$449.91B	107.45	8.57%	5.79%	67.46%	—
PFEPfizer Inc.	$24.07	$136.92B	17.70	-1.65%	11.83%	8.34%	—